Best Options Strategy for NUVL
Looking for the best options strategy for Nuvalent, Inc. (NUVL)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live NUVL option chain right now, and a simple map from your view on NUVL to the strategy that fits it. Model any of them in the calculator before you trade.
About NUVL
Nuvalent, Inc. (NUVL) is a major company in Biotechnology. Options traders on NUVL tend to watch , since these can drive large moves in the share price.
About Nuvalent, Inc.
Nuvalent is a clinical-stage biopharmaceutical company developing targeted cancer therapies. The company's pipeline centers on three main drug candidates, each designed to overcome common limitations of existing treatments. Zidesamtinib targets ROS1-positive lung cancer and is currently in Phase 2 testing through the ARROS-1 trial, addressing issues like drug resistance, side effects affecting the brain, and brain metastases. Neladalkib, in Phase 2 of the ALKOVE-1 trial, works against ALK-driven cancers with similar goals of improving upon earlier-generation inhibitors. A third candidate, NVL-330, targets HER2-mutant tumors in Phase 1 testing. The company also partners with Guardant Health to develop companion diagnostic tests alongside its drug development efforts.
Nuvalent generates value through advancing its drug candidates through clinical trials toward potential regulatory approval and commercialization. The company's revenue model depends on reaching late-stage development and ultimately bringing these therapies to market, where it would earn sales revenue from patients and healthcare systems. Founded in 2017 and based in Cambridge, Massachusetts, Nuvalent operates in the…
Today's top-scoring strategy for NUVL
Our engine ranks defined-risk strategies on the live NUVL chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $110 | $0.12 |
| Sell | 1× | PUT | $115 | $0.50 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Illustrative example at NUVL's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
NUVL is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on NUVL currently price in about 32% implied volatility, versus roughly 112% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$7.82 (±6%) in NUVL by 2026-07-17 — a range of roughly $116 to $131. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on NUVL trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Earnings & IV crush
NUVL's next earnings report is due around August 6, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $9.8B
- Beta (vs market)
- 1.15
- 52-week range
- $71.13–$123.80 (100% up the range)
- Short interest
- 6.6% of float · 0.7 days to cover
How to choose an options strategy for NUVL
Start with your outlook on NUVL, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while NUVL stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open NUVL in the free calculator →
Frequently asked questions
What is the best options strategy for NUVL?
It depends on your outlook. Bullish traders often use a long call or bull call spread on NUVL; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are NUVL options liquid enough to trade?
Nuvalent, Inc. (NUVL) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade NUVL options?
Buying a single NUVL call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade NUVL or any security. Do your own research.
What does Nuvalent, Inc. do?
Nuvalent, Inc. (NUVL) operates in the Biotechnology industry. The "About Nuvalent, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Nuvalent, Inc. pay a dividend?
Nuvalent, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does Nuvalent, Inc. next report earnings?
Nuvalent, Inc.'s next earnings are expected around August 6, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to NUVL
Comparing NUVL with similar names can help you choose the best options strategy:
Company information
- Headquarters
- One Broadway, 14th Floor, Cambridge, MA, 02142, United States
- Industry
- Biotechnology
- Employees
- 234
- CEO
- Dr. James R. Porter Ph.D.
- Phone
- 857 357 7000
- Website
- nuvalent.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.